Loading...
•
Dec 31, 2023
Halozyme Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Takeaways
Halozyme's Q4 2023 revenue increased by 27% year-over-year to $230 million, driven by royalty revenue growth, higher product sales, and an increase in milestone revenue. GAAP diluted EPS was $0.65, and non-GAAP diluted EPS was $0.82. The company is reiterating its 2024 financial guidance and announced a new $750 million share repurchase program.
Q4 revenue increased 27% year-over-year to $230 million.
GAAP diluted EPS was $0.65, and non-GAAP diluted EPS was $0.82.
Reiterating 2024 financial guidance, projecting continued growth.
Announced a new $750 million share repurchase program.
Halozyme
Halozyme
Halozyme Revenue by Segment
Revenue by Segment
Royalties Revenue
CapyFin.com Forward Guidance
The Company is reiterating its financial guidance for 2024, which was initially provided on January 17, 2024.
Positive Outlook
- Total revenue of $915 million to $985 million, representing growth of 10% to 19% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED®
- Revenue from royalties of $500 million to $525 million, representing growth of 12% to 17% over 2023.
- Adjusted EBITDA of $535 million to $585 million, representing growth of 26% to 37% over 2023.
- Non-GAAP diluted earnings per share of $3.55 to $3.90, representing growth of 28% to 41% over 2023.